Christopher Cabell - 21 Feb 2025 Form 4/A - Amendment Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
President & Head of R&D
Signature
/s/ Mark Iwicki, attorney-in-fact
Issuer symbol
IKT
Transactions as of
21 Feb 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
02 Jul 2025, 20:00:09 UTC
Date Of Original Report
25 Feb 2025
Previous filing
22 May 2023
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cabell Christopher President & Head of R&D 1000 N. WEST STREET, SUITE 1200, WILMINGTON /s/ Mark Iwicki, attorney-in-fact 02 Jul 2025 0001814928

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +1,100,705 $0.000000 1,100,705 21 Feb 2025 Common Stock 1,100,705 $2.97 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price.
F2 The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.